Peyronie's disease intervention trials: Methodological challenges and issues

Journal of Sexual Medicine

Volumn 6, Issue 3, 2009, Pages 848-861

  Müller, Alexander ^a,b   Mulhall, John P ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical Trials; Medical Treatment; Methodology; Peyronie's Disease

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; CARNITINE; COLCHICINE; COLLAGENASE; CORTICOSTEROID; DEXAMETHASONE; IBUPROFEN; INTERFERON; LIDOCAINE; PLACEBO; SUPEROXIDE DISMUTASE; TAMOXIFEN; VERAPAMIL;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; INTERNET; MEDLINE; METHODOLOGY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SATISFACTION; PATIENT SELECTION; PEYRONIE DISEASE; PRIORITY JOURNAL; SAMPLE SIZE; SEXUAL FUNCTION; TREATMENT DURATION; ULTRASOUND THERAPY;

EID: 61549143393     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01081.x     Document Type: Article

References (53)

1. Dunsmuir WD, Kirby RS. Francois de la Peyronie (1678-1747): The man and the disease he described. Br J Urol 1996;78:613-22.
2. De la Peyronie R. Sur quelques obstacles, qui s'opposent à l'ejaculaction naturelle de la semence. Mem Acad Chir 1743;1:318.
3. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997;158:1388.
4. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the aetiology of Peyronie's disease. Br J Urol 1982;54:748-50.
5. Schwarzer U, Sommer F, Klotz T, Braun M, Reiferrath B, Engelmann U. The prevalnece of Peyronie's disease: Results of a large survey. BJU Int 2001;88:727-30.
6. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a populatin of men presenting for prostate cancer screening. J Urol 2004;171:2350-3.
7. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F; SIMONA Study Group. Peyronie's disease: Prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2001;40:525-30.
8. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 3007 men with Peyronie's disease. J Urol 2002;168:1075-9.
9. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronies's disease in men over 50-y-old form Southern Brazil. Int J Impot Res 2001;13:291-3.
10. Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948;41:173.
11. Duncan MR, Berman B, Nseyo Uo. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta, -gamma. Scand J Urol Nephrol 1991;25:89-94.
12. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992;70:648-51.
13. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994;151:1522-4.
14. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the aetiology of Peyronie's disease. Br J Urol 1982;54:748-50.
15. Hellstrom WJG, Kendrirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A, Templeton LC, Pryor JL. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon a-2b for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8.
16. Weidner W, Hauck EW, Schnitker J. Potassium Paraaminobenzoate (POTABA™) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-5; discussion 535-6.
17. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006;175:2115-8.
18. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9.
19. Mulhall JP, Montorsi F. Evaluating preference trails of oral phosphdiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006;49:30-7.
20. Levine LA, Estrade CR. Intralesional verapamil for the treatment of Peyronie's disease: A review. Int J Impot Res 2002;14:324-8.
21. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol 1993;149:56-8.
22. Hatzichrostodoulou G, Meisner C, Liske P, Stenzel A, Lahme S. Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie's disease (PD)-First results of a prospective, randomized, placebo-controlled, single-blind study. 4 Supplement abstract no 993. J Urol 2006;175:320.
23. Poulakis V, Skriapas K, de Vries R, Dillenburg W, Ferakis N, Witzsch U, Melekos M, Becht E. Extracorporeal shockwave therapy for Peyronie's disease: An alternative treatment? Asian J Androl 2006;8:361-6.
24. Mirone V, Imbimbo C, Palmieri A, Longo N, Fusco F, Tajana G. A new biopsy technique to investigate Peyronie's disease associated histologic alterations: Results with two different forms of therapy. Eur Urol 2002;42:239-44.
25. Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie's disease. J Urol 2000;163:95-9.
26. Deveci S, Hopps CV, O'brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007;4:485-90.
27. Levine LA, Estrade CR, Strom DW, Matkow TG. Peyronie's disease in younger men: Characteristics and treatment results. J Androl 2003;24:27-32.
28. Kadioglu A, Tefekli A, Erol H, Cayan S, Kandirali E. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie's disease. Int J Impot Res 2000;12:263-7.
29. Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shockwave therapy for Pexronie's disease does not correct penile deformity. Int J Impot Res 2004;16:448-51.
30. Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, Scattoni V, Rigatti P, Pizzini G. Transdermal elecromotive mutli-drug administration for Peyronie's disease: Preliminary results. J Androl 2000;21:85-90.
31. Safarinejad MR. Therapeutic effects of colchicines in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study. Int J Impot Res 2004;16:238-43.
32. Pietro-Castro RM, Leva Vallejo ME, Reueeiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003;91:522-4.
33. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 2001;88:63-7.
34. Cavallini G, Biagiotti G, Koverech A, Vitali O. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's diseases. BJU Int 2002;89:895-900.
35. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's diseases: A randomized and prospective study. Urology 2006;67:1038-42.
36. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single blind study. Urology 1998;51:620-6.
37. Sommer KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997;157:311-5.
38. Manikandan R, Islam W, Srinivasan V, Evans CM. Evaluation of extracorporeal shock wave therapy in Peyronie's disease. Urology 2002;60:795-9.
39. Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie's disease patients: Comparison of three methods. J Sex Med 2007;4:1999-2003.
40. Lebret T, Loison G, Herve HM, Mc Eleny KR, Lugagne PM, Yonneau L, Orsoni JL, Saporta F, Butreau M, Botto H. Extracorporeal shock wave therapy in the treatment of Peyronie's disease: Experience with standard lithotripter (Siemens-multiline). Urology 2002;59:657-61.
41. Bekos A, Arvaniti M, Hatzimouratidis K, Moysidis K, Tzortzis V, Hatzichristou D. The natural history of Peyronie's disease: An ultrasonography-based study. Eur Urol 2008;53:644-50.
42. Hauck EW, Hackstein N, Vosshenrich R. Diagnostic value of magnetic resonance imaging in Peyronie's disease: A comparison both with palpation and ultrasound in the evaluation of plaque formation. Eur Urol 2003;43:293-300.
43. Pryor JP, Ralph DJ. Clinical presentations of Peyronie's disease. Int J Impot Res 2002;14:414-7.
44. Jordan GH, Angermeier KW. Preoperative evaluation of erectile funciton with dynamic infusion cavernosometry/cavernosography in patients undergoing surgery for Peyronie's disease: Correlation with postoperative results. J Urol 1993;150:1138-42.
45. Nelson CJ, Diblasio C, Kendirci M, Hellstrom W, Guhring P, Mulhall JP. The chronology of depression and distress in men with Peyronie's disease. J Sex Med 2008;5:1985-90.
46. Teloken C, Rhoden EL, Meyer Grazziotin T, Teodosio Da Ros C, Sogari PR, Souto CAV. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5.
47. Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: Is it effective? Tech Urol 1997;3:135-9.
48. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int 2001;87:654-7.
49. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999;20:444-8.
50. Di Stasi SM, Giannantoni A, Stepehn RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004;171:1609-10.
51. Hauck EW, Hauptmann A, Schleifper T, Schmelz HU, Altinkilic BM, Weidner W. Questionalble efficacy of extracorporeal shock wave therapy for Peyronie's disease: Results of a prospective approach. J Urol 2004;171:296-9.
52. Husain J, Lynn NN, Jones DK, Collins GN, O'Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie's diseases: Initial experience. BJU Int 2000;86:466-8.
53. Colando F, Nicola M. Peyronie's disease: Ultrasonographic follow-up of ESWT. Arch Ital Urol Androl 2000;72:388-91.